Objective:

To introduce Lacrifill®, a novel therapy for dry eye, to the European market following its CE mark approval.

Key Findings:

• Dry eye disease affects up to 30% of the European population and poses challenges for surgical candidates.
• Lacrifill® offers an individualized approach to dry eye management.
• It is particularly beneficial for patients undergoing ocular surgical procedures.

Interpretation:

Lacrifill® is expected to improve ocular surface health and enhance surgical outcomes for patients with dry eye disease by stabilizing the ocular surface.

Limitations:

• The long-term efficacy and safety of Lacrifill® beyond six months are not yet established.
• Further studies may be needed to assess its impact on various patient demographics and long-term outcomes.

Conclusion:

The launch of Lacrifill® marks a significant advancement in dry eye management, particularly for surgical candidates.